Camici M, Evangelisti L
Life Support Syst. 1986 Jul-Sep;4(3):205-9.
Haemodialysis was performed using heparin (dialysis I: heparin regimen 1, 2000 U/h) in ten patients. These subjects were then given an infusion of prostacyclin, in the form of epoprostenol sodium salt (dialysis II: prostacyclin, 5 ng X kg-1 X min-1), followed by an infusion of prostacyclin and heparin (dialysis III: heparin regimen 2,500 U/h). Absolute platelet count, in vitro platelet aggregation and plasma beta-thromboglobulin decreased during prostacyclin infusion. Haemodialysis neutropenia was improved by prostacyclin. The membrane sieving coefficient factor and ultrafiltration volume were not improved by prostacyclin alone (dialysis II). Prostacyclin together with heparin (dialysis III) showed, 60 minutes after the start, an unchanged sieving coefficient factor compared with that of heparin alone, while the ultrafiltration volume significantly (P less than 0.001) improved. The results of this study confirm those of earlier studies and suggest that prostaglandin I2 together with low-dose heparin improve the biocompatibility and efficiency of dialysis treatment.
对10例患者使用肝素进行血液透析（透析I：肝素方案1，2000 U/h）。然后给这些受试者输注前列环素，形式为依前列醇钠（透析II：前列环素，5 ng·kg⁻¹·min⁻¹），随后输注前列环素和肝素（透析III：肝素方案2，500 U/h）。在输注前列环素期间，绝对血小板计数、体外血小板聚集和血浆β-血小板球蛋白降低。前列环素改善了血液透析性中性粒细胞减少。单独使用前列环素（透析II）时，膜筛选系数因子和超滤量未得到改善。前列环素与肝素联合使用（透析III），在开始60分钟后，与单独使用肝素相比，筛选系数因子未改变，而超滤量显著（P<0.001）改善。本研究结果证实了早期研究结果，并表明前列腺素I2与低剂量肝素一起可改善透析治疗的生物相容性和效率。
